With over 29 million
Americans living with diabetes, and more than 86 million with prediabetes, this
disease is the seventh leading cause of death and swallows approximately 20% of
nationwide healthcare spending, according to Centers for Disease Control and
Prevention (CDC) statistics (http://nnw.fm/uUEx3). Healthcare officials,
patients and doctors alike are always actively searching for new therapies or
innovative yet affordable treatments to combat this disease.
This is where leading
biopharmaceutical company MannKind Corporation (NASDAQ: MNKD) and its
groundbreaking inhalable insulin product Afrezza® come in. Touted as the first
successful insulin inhaler on the U.S. market, Afrezza is a fast-acting
inhalable insulin powder designed to be used in conjunction with regular type 1
and 2 diabetes treatments to help lower post-meal blood sugar spikes.
Beginning in July, MannKind
relaunched Afrezza Inhalation Powder on the domestic market under its own
branding, and the treatment is now available with major wholesalers, as well as
by prescription in any retail pharmacy.
Leveraging its two-year
experience in patient selection and copayment, the company has also announced
several programs to promote patients’ access to Afrezza therapy. These include:
Enhanced copay assistance
designed to lower insured patients’ out-of-pocket cost to $15 per month
Patient reimbursement
support program, MannKind Cares
Bureau to educate and inform
healthcare providers about the benefits of Afrezza
New titration pack that
allows patients new to Afrezza more flexibility in adjusting their daily dosage
The new programs will join
MannKind’s national salesforce, all of whom have extensive experience with
diabetes and Afrezza, in its efforts to help enhance and streamline patients’
and providers’ experience with this key therapy. The company is committed to
ensuring the treatment remains available to all diabetes patients in the U.S.,
without any disruption in supply.
The July relaunch came after
the company released six more analyses of the pre-meal treatment, demonstrating
a faster onset and shorter duration of action than with mealtime fast-acting
insulin treatments. The findings, presented at the 76th scientific session of
the American Diabetes Association, show that, compared to Eli Lilly and
Company’s (NYSE: LLY) insulin lispro injection, Afrezza has a 50% faster onset
and a 2-3-hour shorter duration of action.
The data supports the use of
this therapy for rapidly controlling high glucose levels, according to the
chief medical officer of MannKind, Raymond W. Urbanski, MD, PhD. Unlike
injectable insulin, which risks causing hypoglycemia after a meal if dosed
incorrectly, Afrezza works in the body more rapidly and leaves the bloodstream
faster, offering an ideal balance between glucose control and a lower risk of
hypoglycemia.
To find out more about
MannKind Corp. and its innovative Afrezza Inhalation Powder insulin, visit
www.MannkindCorp.com
About
QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment